Joy Karmakar

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Selective isoxazolopyrimidine PAT1 (SLC26A6) inhibitors for therapy of intestinal disorders”.

Selective isoxazolopyrimidine PAT1 (SLC26A6) inhibitors for therapy of intestinal disorders

RSC Medicinal Chemistry(2023)10.1039/d3md00302g

N/A

0DataRank · unranked

6 citations

Joy Karmakar, Peter M. Haggie, Joseph‐Anthony Tan, Riya Master, Keerthana Ramaswamy +4 more

352 SLC26A3 (downregulated in adenoma) inhibitors with extracellular site of action block intestinal fluid absorption and reduce constipation in mice

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01279-1

N/A

0DataRank · unranked

0 citations

Joy Karmakar, Marc O. Anderson, O. Cil, Lívia de Souza Gonçalves

175 Nanomolar potency 3-carboxy-2-methylbenzofuran pendrin inhibitors for treatment of cystic fibrosis

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01106-2

N/A

0DataRank · unranked

0 citations

Lívia de Souza Gonçalves, Joy Karmakar, Marc O. Anderson, O. Cil, Ryan G. Master

High potency 3-carboxy-2-methylbenzofuran pendrin inhibitors as novel diuretics

European Journal of Medicinal Chemistry(2024)10.1016/j.ejmech.2024.117133

N/A

0DataRank · unranked

2 citations

Joy Karmakar, Peter M. Haggie, Joseph Anthony-Tan, Tifany Chu, A.S. Verkman +3 more